US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS

359.58

-7.1500-1.95%

Post-market: 359.580.00000.00%17:29 EDT

Volume:346.04K

Turnover:123.94M

Market Cap:40.99B

PE:64.33

High:361.03

Open:356.50

Low:352.86

Close:366.73

52wk High:385.22

52wk Low:253.95

Shares:114.00M

Float Shares:85.69M

Volume Ratio:1.20

T/O Rate:0.40%

Dividend:- -

Dividend Rate:- -

EPS(TTM):5.59

EPS(LYR):2.47

ROE:14.66%

ROA:7.46%

PB:7.92

PE(LYR):145.58

Loading ...

Overview Company News Filings

BeOne Medicines (ONC) Stock Looks Expensive Even With Strong Pipeline Hopes

Simply Wall St.

How Chemotherapy-Free Phase 3 MCL Success At BeOne Medicines (ONC) Has Changed Its Investment Story

Simply Wall St.

BeOne Medicines (ONC) Gets a Buy from Barclays

BeOne Medicines Advances Sonrotoclax Formulation Study, Signaling Progress in ONC Pipeline

BeOne Medicines treatment of pancreatic cancer granted orphan status

BEIGENE Awards Aggregate 33,400 Restricted Stock Units Represented by American Depositary Shares

BEIGENE Shares Surge Over 4% on Positive Phase 3 Clinical Trial News for Zanubrutinib

Analysts Offer Insights on Healthcare Companies: Jazz Pharmaceuticals (JAZZ), BeOne Medicines (ONC) and Zevra Therapeutics (ZVRA)

BEIGENE Reports Positive Phase 3 Trial Results for BRUKINSA® in First-Line Treatment of Mantle Cell Lymphoma

BeOne Medicines' Potential Chemotherapy-Free Lymphoma Treatment Meets Primary Endpoint in Phase 3 Study

MT Newswires Live

Chinese Biopharma Stocks Rally as Investors Favor Healthcare over AI

BEIGENE Subsidiary to Pay Approximately 446 Million Yuan in Back Taxes, No Penalty Involved

BeOne Medicines’ Real‑World Lung Cancer Study Puts Tislelizumab Under the Market Microscope

BeOne Medicines (ONC) Investors Track New Data from BeiGene’s Chronic Urticaria Trial

BeOne Medicines’ BGB-45035 Trial Completion: What Early Skin Data Could Mean for ONC Investors

BEIGENE Announces Grant of Share Options, Restricted Share Units, and Performance Share Units

BeOne Revenue Expected to Grow on Strong Brukinsa Sales -- Market Talk

BeOne Medicines Advances BGB-58067 With Key Drug-Interaction Study in Healthy Volunteers

BeOne Medicines (ONC) Gets a Buy from Barclays

BeOne Says Updated Results for Cancer Drug Tacabrutideg Show 'Durable' Responses

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://au1.tigerplaytime.com/stock/ONC/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ONC","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ONC\",,,,,undefined,":{"symbol":"ONC","market":"US","secType":"STK","nameCN":"BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS","latestPrice":359.58,"timestamp":1788206400000,"preClose":366.73,"halted":0,"volume":346041,"hourTrading":{"tag":"盘后","latestPrice":359.58,"preClose":359.58,"latestTime":"17:29 EDT","volume":48081,"amount":17289033.293399997,"timestamp":1788211783604,"change":0,"changeRate":0,"amplitude":0.007564},"delay":0,"changeRate":-0.0194966323998583,"floatShares":85693500,"shares":113999999,"eps":5.589356,"marketStatus":"Post-Mkt","change":-7.15,"latestTime":"08-31 17:45:58 EDT","open":356.5,"high":361.03,"low":352.86,"amount":123943453.18083,"amplitude":0.022278,"askPrice":362.94,"askSize":8,"bidPrice":352.39,"bidSize":5,"shortable":3,"etf":0,"ttmEps":5.589356,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1788220800000},"marketStatusCode":4,"adr":0,"adrRate":13,"exchange":"NASDAQ","adjPreClose":366.73,"preHourTrading":{"tag":"盘前","latestPrice":356.2,"preClose":366.73,"latestTime":"09:28 EDT","volume":10872,"amount":3977952.8184,"timestamp":1788182883090,"change":-10.53,"changeRate":-0.028713,"amplitude":0.015406},"postHourTrading":{"tag":"盘后","latestPrice":359.58,"preClose":359.58,"latestTime":"17:29 EDT","volume":48081,"amount":17289033.293399997,"timestamp":1788211783604,"change":0,"changeRate":0,"amplitude":0.007564},"volumeRatio":1.201262,"impliedVol":0.3342,"impliedVolPercentile":0.0239},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ONC\",,,,,undefined,":{"symbol":"ONC","floatShares":85693500,"roa":"7.46%","roe":"14.66%","lyrEps":2.469999,"volumeRatio":1.201262,"shares":113999999,"dividePrice":0,"high":361.03,"amplitude":0.022278,"preClose":366.73,"low":352.86,"week52Low":253.9475,"pbRate":"7.92","psRate":"6.69","week52High":385.22,"institutionHeld":0,"latestPrice":359.58,"committee":-0.230769,"eps":5.589356,"divideRate":0,"volume":346041,"delay":0,"ttmEps":5.589356,"open":356.5,"prevYearClose":303.81,"prevWeekClose":366.73,"prevMonthClose":316.01,"prevQuarterClose":284.97,"fiveDayClose":371.98,"twentyDayClose":313.77,"sixtyDayClose":279.93},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ONC\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-05","symbol":"ONC","fiscalQuarterEnding":"2026/06","expectedEps":1.4,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1785902400000,"reportTimeType":"pre","actualEps":2.05},{"market":"US","date":"2026-05-06","symbol":"ONC","fiscalQuarterEnding":"2026/03","expectedEps":0.73,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1778040000000,"reportTimeType":"post","actualEps":1.96},{"market":"US","date":"2026-02-26","symbol":"ONC","fiscalQuarterEnding":"2025/12","expectedEps":1.6,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1772082000000,"reportTimeType":"pre","actualEps":0.58},{"market":"US","date":"2025-11-06","symbol":"ONC","fiscalQuarterEnding":"2025/09","expectedEps":0.72,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1762405200000,"reportTimeType":"post","actualEps":1.09},{"date":"2025-08-30","symbol":"ONC","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1756540800000,"name":null,"time":"Pre-MKt","dateTimestamp":1756526400000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ONC\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ONC\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.2857,"buy":0.6786,"hold":0,"sell":0.0357,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6786,"analysts":28,"updateTime":1783915200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ONC\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ONC","date":"2026-08-28","current":63.577986,"percent":0.718085,"low":-217.585346,"twenty":-72.771126,"median":-25.664335,"eighty":109.774239,"high":609.337035,"avg":44.248712,"sd":210.963884,"marketCap":42352812163},"quantilePoints":[{"date":"2024-05-31","current":-19.860847,"twenty":-20.46703,"median":-20.284421,"eighty":-20.042184,"marketCap":15579384952},{"date":"2024-06-07","current":-20.864085,"twenty":-20.930269,"median":-20.558927,"eighty":-20.042184,"marketCap":16366351618},{"date":"2024-06-14","current":-21.694058,"twenty":-21.409839,"median":-20.844737,"eighty":-20.30869,"marketCap":17017405001},{"date":"2024-06-21","current":-20.966373,"twenty":-21.331475,"median":-20.876952,"eighty":-20.46703,"marketCap":16446589390},{"date":"2024-06-28","current":-19.234246,"twenty":-21.331475,"median":-20.825389,"eighty":-19.981739,"marketCap":15087861974},{"date":"2024-07-05","current":-19.83401,"twenty":-21.208618,"median":-20.693442,"eighty":-19.760805,"marketCap":15558333278},{"date":"2024-07-12","current":-20.525989,"twenty":-21.135228,"median":-20.465877,"eighty":-19.641074,"marketCap":16101139655},{"date":"2024-07-19","current":-20.872652,"twenty":-21.016911,"median":-20.525989,"eighty":-19.707798,"marketCap":16373071895},{"date":"2024-07-26","current":-21.924783,"twenty":-21.374239,"median":-20.660298,"eighty":-19.760805,"marketCap":17198391533},{"date":"2024-08-02","current":-22.081827,"twenty":-21.704901,"median":-20.777003,"eighty":-19.839377,"marketCap":17321581561},{"date":"2024-08-09","current":-37.033118,"twenty":-22.009534,"median":-20.868368,"eighty":-19.874904,"marketCap":19394058972},{"date":"2024-08-16","current":-39.443432,"twenty":-22.36867,"median":-20.966373,"eighty":-19.937065,"marketCap":20656328240},{"date":"2024-08-23","current":-39.274234,"twenty":-33.284244,"median":-21.171036,"eighty":-20.00126,"marketCap":20567720015},{"date":"2024-08-30","current":-38.860864,"twenty":-37.912544,"median":-21.248991,"eighty":-20.190606,"marketCap":20351240040},{"date":"2024-09-06","current":-38.812817,"twenty":-38.506257,"median":-21.456019,"eighty":-20.300725,"marketCap":20326078245},{"date":"2024-09-13","current":-40.29759,"twenty":-38.865563,"median":-21.710093,"eighty":-20.355918,"marketCap":21103646159},{"date":"2024-09-20","current":-41.008162,"twenty":-39.353261,"median":-21.954664,"eighty":-20.405766,"marketCap":21475769498},{"date":"2024-09-27","current":-44.343793,"twenty":-39.883427,"median":-22.072098,"eighty":-20.507104,"marketCap":23222622772},{"date":"2024-10-04","current":-49.961787,"twenty":-40.117185,"median":-22.410559,"eighty":-20.525989,"marketCap":26164738255},{"date":"2024-10-11","current":-47.875901,"twenty":-40.317892,"median":-22.855632,"eighty":-20.558927,"marketCap":25072369873},{"date":"2024-10-18","current":-44.402313,"twenty":-41.008162,"median":-37.033118,"eighty":-20.627155,"marketCap":23253269086},{"date":"2024-10-25","current":-43.1532,"twenty":-43.068033,"median":-37.882149,"eighty":-20.693442,"marketCap":22599114920},{"date":"2024-11-01","current":-41.429716,"twenty":-43.148001,"median":-38.271158,"eighty":-20.724275,"marketCap":21696535276},{"date":"2024-11-08","current":-41.685343,"twenty":-43.068033,"median":-38.746669,"eighty":-20.777003,"marketCap":21830405481},{"date":"2024-11-15","current":-24.188369,"twenty":-42.835701,"median":-38.506257,"eighty":-20.825389,"marketCap":20104967290},{"date":"2024-11-22","current":-24.46985,"twenty":-42.494274,"median":-38.062423,"eighty":-20.864085,"marketCap":20240962418},{"date":"2024-11-29","current":-27.613239,"twenty":-42.262623,"median":-37.45966,"eighty":-20.870939,"marketCap":22851200825},{"date":"2024-12-06","current":-26.519964,"twenty":-42.078114,"median":-35.811244,"eighty":-20.886386,"marketCap":21862847938},{"date":"2024-12-13","current":-23.158686,"twenty":-41.984053,"median":-26.690447,"eighty":-20.951062,"marketCap":19077141333},{"date":"2024-12-20","current":-22.876382,"twenty":-41.961072,"median":-26.519964,"eighty":-21.016911,"marketCap":18791641889},{"date":"2024-12-27","current":-23.581122,"twenty":-41.848457,"median":-25.970587,"eighty":-21.108807,"marketCap":19365505627},{"date":"2025-01-03","current":-23.522344,"twenty":-41.738903,"median":-25.015322,"eighty":-21.169159,"marketCap":19262068568},{"date":"2025-01-10","current":-23.039426,"twenty":-41.667895,"median":-24.95255,"eighty":-21.188412,"marketCap":18831625271},{"date":"2025-01-17","current":-27.361812,"twenty":-41.564427,"median":-24.990614,"eighty":-21.226086,"marketCap":22387798297},{"date":"2025-01-24","current":-28.60727,"twenty":-41.429716,"median":-25.817461,"eighty":-21.248991,"marketCap":23666613889},{"date":"2025-01-31","current":-29.006926,"twenty":-41.129457,"median":-26.292693,"eighty":-21.405551,"marketCap":23976726670},{"date":"2025-02-07","current":-29.003485,"twenty":-41.095232,"median":-26.532547,"eighty":-21.456019,"marketCap":23849552911},{"date":"2025-02-14","current":-29.812673,"twenty":-41.008162,"median":-26.754345,"eighty":-21.694058,"marketCap":24634934161},{"date":"2025-02-21","current":-32.964646,"twenty":-40.974605,"median":-27.361812,"eighty":-21.704901,"marketCap":27250381776},{"date":"2025-02-28","current":-45.085214,"twenty":-41.025576,"median":-28.423545,"eighty":-21.711581,"marketCap":29070314911},{"date":"2025-03-07","current":-41.087466,"twenty":-41.189509,"median":-28.729221,"eighty":-21.882341,"marketCap":26492622821},{"date":"2025-03-14","current":-43.209977,"twenty":-41.608729,"median":-28.790129,"eighty":-21.948688,"marketCap":27861188167},{"date":"2025-03-21","current":-42.024306,"twenty":-41.961072,"median":-29.003485,"eighty":-22.009534,"marketCap":27096684166},{"date":"2025-03-28","current":-44.59433,"twenty":-42.028738,"median":-29.052749,"eighty":-22.054545,"marketCap":28753799426},{"date":"2025-04-04","current":-39.846019,"twenty":-42.270172,"median":-29.231496,"eighty":-22.077935,"marketCap":25692155286},{"date":"2025-04-11","current":-38.484462,"twenty":-42.209323,"median":-29.379987,"eighty":-22.177258,"marketCap":24814242135},{"date":"2025-04-17","current":-38.603,"twenty":-42.109763,"median":-29.75631,"eighty":-22.326782,"marketCap":24890673891},{"date":"2025-04-25","current":-40.929408,"twenty":-42.213935,"median":-30.85745,"eighty":-22.4234,"marketCap":26390709308},{"date":"2025-05-02","current":-42.799955,"twenty":-42.322726,"median":-33.161649,"eighty":-22.493794,"marketCap":27596811853},{"date":"2025-05-09","current":-63.824658,"twenty":-42.611855,"median":-33.528671,"eighty":-22.601969,"marketCap":25042625921},{"date":"2025-05-16","current":-62.94985,"twenty":-42.804476,"median":-34.892623,"eighty":-22.71748,"marketCap":24699380815},{"date":"2025-05-23","current":-72.041871,"twenty":-43.150081,"median":-36.84391,"eighty":-22.787779,"marketCap":28266780880},{"date":"2025-05-30","current":-74.527648,"twenty":-43.429182,"median":-37.087829,"eighty":-22.808465,"marketCap":29242115209},{"date":"2025-06-06","current":-77.688492,"twenty":-43.794804,"median":-38.030583,"eighty":-22.84042,"marketCap":30482322820},{"date":"2025-06-13","current":-89.808695,"twenty":-44.177303,"median":-38.271158,"eighty":-22.941372,"marketCap":35237878321},{"date":"2025-06-20","current":-76.439732,"twenty":-44.40516,"median":-38.484462,"eighty":-23.038971,"marketCap":29992352055},{"date":"2025-06-27","current":-76.95683,"twenty":-44.800569,"median":-38.641761,"eighty":-23.063278,"marketCap":30195243589},{"date":"2025-07-03","current":-74.11053,"twenty":-45.138397,"median":-38.836841,"eighty":-23.158686,"marketCap":29078452032},{"date":"2025-07-11","current":-76.495446,"twenty":-45.905367,"median":-39.006759,"eighty":-23.171606,"marketCap":30014212230},{"date":"2025-07-18","current":-87.653233,"twenty":-47.435675,"median":-39.313748,"eighty":-23.176246,"marketCap":34392148550},{"date":"2025-07-25","current":-89.648478,"twenty":-48.541013,"median":-39.640999,"eighty":-23.189441,"marketCap":35175014575},{"date":"2025-08-01","current":-91.060669,"twenty":-60.626235,"median":-39.865155,"eighty":-23.250607,"marketCap":35729110635},{"date":"2025-08-08","current":-184.757225,"twenty":-63.824658,"median":-40.051934,"eighty":-23.50984,"marketCap":32820458238},{"date":"2025-08-15","current":-191.818248,"twenty":-64.911375,"median":-40.112152,"eighty":-23.522344,"marketCap":34074785315},{"date":"2025-08-22","current":-194.469228,"twenty":-72.041871,"median":-40.222554,"eighty":-23.535152,"marketCap":34545708113},{"date":"2025-08-29","current":-184.552827,"twenty":-72.8475,"median":-40.343171,"eighty":-23.581122,"marketCap":32784148770},{"date":"2025-09-05","current":-197.417514,"twenty":-73.864189,"median":-40.425269,"eighty":-23.723244,"marketCap":35069444682},{"date":"2025-09-12","current":-208.147892,"twenty":-74.224679,"median":-40.801852,"eighty":-23.82061,"marketCap":36975599617},{"date":"2025-09-19","current":-212.503459,"twenty":-75.66857,"median":-40.932054,"eighty":-23.865007,"marketCap":37749326897},{"date":"2025-09-26","current":-203.715512,"twenty":-76.587723,"median":-41.008162,"eighty":-23.928977,"marketCap":36188227257},{"date":"2025-10-03","current":-213.916471,"twenty":-77.910534,"median":-41.112345,"eighty":-23.950329,"marketCap":38000335866},{"date":"2025-10-10","current":-208.109485,"twenty":-81.639564,"median":-41.598105,"eighty":-24.044918,"marketCap":36968777077},{"date":"2025-10-17","current":-197.090466,"twenty":-85.2662,"median":-41.668284,"eighty":-24.084563,"marketCap":35011347487},{"date":"2025-10-24","current":-192.138725,"twenty":-87.584871,"median":-41.753651,"eighty":-24.09529,"marketCap":34131715179},{"date":"2025-10-31","current":-191.016991,"twenty":-89.061223,"median":-41.811067,"eighty":-24.120226,"marketCap":33932449287},{"date":"2025-11-07","current":-207.03708,"twenty":-89.680521,"median":-41.96845,"eighty":-24.175905,"marketCap":36778273935},{"date":"2025-11-14","current":594.631071,"twenty":-89.43801,"median":-41.811067,"eighty":-24.044918,"marketCap":40761959883},{"date":"2025-11-21","current":563.847015,"twenty":-89.201535,"median":-41.753651,"eighty":-23.82061,"marketCap":38651712910},{"date":"2025-11-28","current":549.835185,"twenty":-89.104768,"median":-41.685343,"eighty":-23.530029,"marketCap":37691201965},{"date":"2025-12-05","current":534.967794,"twenty":-89.063642,"median":-41.61723,"eighty":-23.184163,"marketCap":36672042310},{"date":"2025-12-12","current":517.921144,"twenty":-88.590694,"median":-41.129457,"eighty":-23.039198,"marketCap":35503494432},{"date":"2025-12-19","current":495.611986,"twenty":-88.19516,"median":-41.047814,"eighty":-22.787779,"marketCap":33974201659},{"date":"2025-12-26","current":503.21518,"twenty":-87.945005,"median":-40.950457,"eighty":-22.473183,"marketCap":34495400571},{"date":"2026-01-02","current":490.430192,"twenty":-87.636143,"median":-40.899758,"eighty":-22.105685,"marketCap":33618989662},{"date":"2026-01-09","current":517.162439,"twenty":-87.22937,"median":-40.570085,"eighty":-21.930759,"marketCap":35451485198},{"date":"2026-01-16","current":546.090088,"twenty":-85.828543,"median":-40.382553,"eighty":-21.503627,"marketCap":37434475537},{"date":"2026-01-23","current":546.929506,"twenty":-85.639801,"median":-40.307741,"eighty":-21.22036,"marketCap":37492017667},{"date":"2026-01-30","current":564.993144,"twenty":-85.550958,"median":-40.153659,"eighty":-20.966373,"marketCap":38730280050},{"date":"2026-02-06","current":560.150346,"twenty":-85.195011,"median":-40.102874,"eighty":-20.825389,"marketCap":38398306221},{"date":"2026-02-13","current":559.214072,"twenty":-84.275105,"median":-39.916618,"eighty":-20.627155,"marketCap":38334124614},{"date":"2026-02-20","current":572.225057,"twenty":-83.309792,"median":-39.846883,"eighty":-20.486836,"marketCap":39226027634},{"date":"2026-02-27","current":124.64483,"twenty":-82.630374,"median":-39.542215,"eighty":-20.122622,"marketCap":35764714896},{"date":"2026-03-06","current":113.265677,"twenty":-81.639564,"median":-39.274234,"eighty":-19.815709,"marketCap":32499660582},{"date":"2026-03-13","current":110.254986,"twenty":-80.905934,"median":-38.936161,"eighty":-19.52935,"marketCap":31635793773},{"date":"2026-03-20","current":109.257937,"twenty":-80.698984,"median":-38.812817,"eighty":-19.378455,"marketCap":31349707731},{"date":"2026-03-27","current":107.028105,"twenty":-78.593786,"median":-38.554628,"eighty":106.63856,"marketCap":30709895147},{"date":"2026-04-02","current":119.197503,"twenty":-77.951,"median":-38.396659,"eighty":109.305857,"marketCap":34201697271},{"date":"2026-04-10","current":121.122038,"twenty":-77.761122,"median":-38.192039,"eighty":109.972102,"marketCap":34753909865},{"date":"2026-04-17","current":123.949552,"twenty":-77.38927,"median":-37.882149,"eighty":113.865362,"marketCap":35565216938},{"date":"2026-04-24","current":115.875632,"twenty":-77.050014,"median":-37.033118,"eighty":115.720164,"marketCap":33248542844},{"date":"2026-05-01","current":114.357667,"twenty":-76.68,"median":-35.397875,"eighty":115.720164,"marketCap":32812988374},{"date":"2026-05-08","current":68.695502,"twenty":-76.462018,"median":-34.468285,"eighty":115.560959,"marketCap":35242166242},{"date":"2026-05-15","current":66.012693,"twenty":-76.246744,"median":-33.418249,"eighty":115.518333,"marketCap":33865831800},{"date":"2026-05-22","current":67.096218,"twenty":-76.102676,"median":-31.546239,"eighty":115.492019,"marketCap":34421701930},{"date":"2026-05-29","current":62.970154,"twenty":-75.880486,"median":-30.693232,"eighty":115.373164,"marketCap":32304948475},{"date":"2026-06-05","current":60.662245,"twenty":-75.223997,"median":-29.59006,"eighty":115.163248,"marketCap":31120945098},{"date":"2026-06-12","current":56.401824,"twenty":-74.640704,"median":-29.253094,"eighty":114.989528,"marketCap":28935263747},{"date":"2026-06-18","current":56.924083,"twenty":-74.490547,"median":-29.223519,"eighty":114.833736,"marketCap":29203193149},{"date":"2026-06-26","current":59.667569,"twenty":-74.312777,"median":-29.026044,"eighty":114.683445,"marketCap":30610656318},{"date":"2026-07-02","current":63.004827,"twenty":-74.195313,"median":-28.914242,"eighty":114.357667,"marketCap":32322736319},{"date":"2026-07-10","current":65.624791,"twenty":-74.135535,"median":-28.781271,"eighty":113.811576,"marketCap":33666830293},{"date":"2026-07-17","current":68.786518,"twenty":-74.11053,"median":-28.668245,"eighty":113.265677,"marketCap":35288859332},{"date":"2026-07-24","current":70.81271,"twenty":-74.11053,"median":-28.275697,"eighty":112.626442,"marketCap":36328336476},{"date":"2026-07-31","current":69.796363,"twenty":-73.864189,"median":-27.361812,"eighty":112.074132,"marketCap":35806930294},{"date":"2026-08-07","current":57.188468,"twenty":-73.321375,"median":-26.690447,"eighty":111.218799,"marketCap":37498879034},{"date":"2026-08-14","current":61.733374,"twenty":-72.9906,"median":-26.519964,"eighty":110.411886,"marketCap":40479005230},{"date":"2026-08-21","current":64.013629,"twenty":-72.865597,"median":-26.24637,"eighty":109.877808,"marketCap":41974184913},{"date":"2026-08-28","current":64.591063,"twenty":-72.771126,"median":-25.664335,"eighty":109.774239,"marketCap":42352812163}],"updateTime":1788187724345},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ONC\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2651544933","title":"BeOne Medicines (ONC) Stock Looks Expensive Even With Strong Pipeline Hopes","url":"https://stock-news.laohu8.com/highlight/detail?id=2651544933","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651544933?lang=en_us&edition=fundamental","pubTime":"2026-07-16 18:33","pubTimestamp":1784198003,"startTime":"0","endTime":"0","summary":"BeOne Medicines has delivered a 61.1% return over the past three years, yet its current valuation screens as overvalued on market multiples and only middling on broader checks. This raises the question of how much optimism is already reflected in the share price.\n\nA 61.1% three year return suggests investors have already priced in a meaningful amount of good news for BeOne Medicines.\nRecent analyst upgrades tied to the chronic lymphocytic leukemia franchise and solid tumor pipeline can...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-onc/beone-medicines/news/beone-medicines-onc-stock-looks-expensive-even-with-strong-p","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-onc/beone-medicines/news/beone-medicines-onc-stock-looks-expensive-even-with-strong-p","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["MDCO","BK4585","BK4139","BK4526","ONC","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651482014","title":"How Chemotherapy-Free Phase 3 MCL Success At BeOne Medicines (ONC) Has Changed Its Investment Story","url":"https://stock-news.laohu8.com/highlight/detail?id=2651482014","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651482014?lang=en_us&edition=fundamental","pubTime":"2026-07-15 05:23","pubTimestamp":1784064190,"startTime":"0","endTime":"0","summary":"BeOne Medicines Ltd. recently reported positive topline results from its Phase 3 MANGROVE trial, where BRUKINSA (zanubrutinib) plus rituximab significantly improved progression-free survival versus bendamustine plus rituximab in previously untreated mantle cell lymphoma.\nThis is the first global Phase 3 study to show a chemotherapy-free, rituximab maintenance-free regimen can match or exceed standard chemoimmunotherapy, potentially sparing patients around two years of infusion treatment...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-onc/beone-medicines/news/how-chemotherapy-free-phase-3-mcl-success-at-beone-medicines","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-onc/beone-medicines/news/how-chemotherapy-free-phase-3-mcl-success-at-beone-medicines","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4526","BK4585","BK4139","ONC","BK4588","MDCO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651150175","title":"BeOne Medicines (ONC) Gets a Buy from Barclays","url":"https://stock-news.laohu8.com/highlight/detail?id=2651150175","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651150175?lang=en_us&edition=fundamental","pubTime":"2026-07-14 16:37","pubTimestamp":1784018241,"startTime":"0","endTime":"0","summary":"In a report released today, Etzer Darout from Barclays maintained a Buy rating on BeOne Medicines, with a price target of $403.00. Darout covers th...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/beone-medicines-onc-gets-a-buy-from-barclays-blurbs-news-3?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/beone-medicines-onc-gets-a-buy-from-barclays-blurbs-news-3?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MDCO","BK4585","ONC","BK4526","BK4139","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650750489","title":"BeOne Medicines Advances Sonrotoclax Formulation Study, Signaling Progress in ONC Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2650750489","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650750489?lang=en_us&edition=fundamental","pubTime":"2026-07-10 00:31","pubTimestamp":1783614692,"startTime":"0","endTime":"0","summary":"BeOne Medicines ($ONC) announced an update on their ongoing clinical study. BeOne Medicines is running a Phase 1 study in healthy adults to test ho...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/beone-medicines-advances-sonrotoclax-formulation-study-signaling-progress-in-onc-pipeline?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/beone-medicines-advances-sonrotoclax-formulation-study-signaling-progress-in-onc-pipeline?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PRGS","BK4588","BK4585","BK4139","MDCO","ONC","BK4097","LU2065732104.USD","BK4526"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650978219","title":"BeOne Medicines treatment of pancreatic cancer granted orphan status","url":"https://stock-news.laohu8.com/highlight/detail?id=2650978219","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650978219?lang=en_us&edition=fundamental","pubTime":"2026-07-09 23:00","pubTimestamp":1783609213,"startTime":"0","endTime":"0","summary":"BeOne Medicines (ONC)’ MTA-cooperative PRMT5 inhibitor was granted FDA orphan designation as a treatment of pancreatic cancer, according to a post ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/beone-medicines-treatment-of-pancreatic-cancer-granted-orphan-status-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/beone-medicines-treatment-of-pancreatic-cancer-granted-orphan-status-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ONC","LABU","BK4588","MDCO","BK4585","BK4139","BK4526"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124370507","title":"BEIGENE Awards Aggregate 33,400 Restricted Stock Units Represented by American Depositary Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=1124370507","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1124370507?lang=en_us&edition=fundamental","pubTime":"2026-07-08 17:06","pubTimestamp":1783501565,"startTime":"0","endTime":"0","summary":"BEIGENE (HKEX: 06160) has announced that on July 2, 2026, the Compensation Committee of the Board of Directors, pursuant to the terms of the 2016 Option and Incentive Plan, granted a total of 33,400...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1588","BK4139","BK0239","BK1583","06160","LU1303224171.USD","ONC","BK4585","688235","BK4588","LU1770034418.SGD","LU1251922891.USD","LU1719994722.HKD","BK4526","BK1161","BK1500","KURE","LU1969619763.USD","LU2328871848.SGD","LU0588546209.SGD","LU0307460666.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1163772490","title":"BEIGENE Shares Surge Over 4% on Positive Phase 3 Clinical Trial News for Zanubrutinib","url":"https://stock-news.laohu8.com/highlight/detail?id=1163772490","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1163772490?lang=en_us&edition=fundamental","pubTime":"2026-07-03 09:43","pubTimestamp":1783042997,"startTime":"0","endTime":"0","summary":"Shares of BEIGENE (HKEX: 06160) rose more than 4% in early trading. At the time of writing, the stock was up 4.58% to HK$182.7, with a turnover of HK$81.56 million.The increase follows the company's...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LU1251922891.USD","BK4139","VXUS","LU1770034418.SGD","BK0239","LU1303224171.USD","LU0588546209.SGD","LU1969619763.USD","LU2328871848.SGD","ONC","BK1588","BK4526","BK4585","BK1500","LU0307460666.USD","06160","LU1719994722.HKD","BK1583","BK1161","688235"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648510936","title":"Analysts Offer Insights on Healthcare Companies: Jazz Pharmaceuticals (JAZZ), BeOne Medicines (ONC) and Zevra Therapeutics (ZVRA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2648510936","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648510936?lang=en_us&edition=fundamental","pubTime":"2026-07-01 19:40","pubTimestamp":1782906024,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Jazz Pharmaceuticals (JAZZ), BeOne Medicines (ONC) a...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-jazz-pharmaceuticals-jazz-beone-medicines-onc-and-zevra-therapeutics-zvra-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-jazz-pharmaceuticals-jazz-beone-medicines-onc-and-zevra-therapeutics-zvra-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0154245756.USD","HCSG","LABU","LU0889565916.HKD","XBI","BK4007","JAZZ","BK4581","BK4588","LU0029874061.USD","LU0109394709.USD","MDCO","LU0128526141.USD","BK4139","BK4585","IE00BN0W2V16.EUR","LU0154245673.USD","XLV","ZVRA","BK4533","BK4137","IE00BN0W2W23.USD","LU0320765992.SGD","BK4526","BK4532","LU0823416689.USD","ONC","IE00BN0W2T93.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183010146","title":"BEIGENE Reports Positive Phase 3 Trial Results for BRUKINSA® in First-Line Treatment of Mantle Cell Lymphoma","url":"https://stock-news.laohu8.com/highlight/detail?id=1183010146","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1183010146?lang=en_us&edition=fundamental","pubTime":"2026-06-30 22:12","pubTimestamp":1782828767,"startTime":"0","endTime":"0","summary":"BEIGENE announced positive results from the MANGROVE Phase 3 clinical trial (BGB-3111-306;NCT04002297).The study evaluated its foundational, self-developed BTK inhibitor, BRUKINSA® (zanubrutinib),...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0307460666.USD","BK4139","BK1500","BK4526","ONC","LU2328871848.SGD","06160","LU1303224171.USD","LU0588546209.SGD","BK1588","BK1583","LU1719994722.HKD","BK1161","688235","LU1251922891.USD","LU1770034418.SGD","LU1969619763.USD","BK0239","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647453719","title":"BeOne Medicines' Potential Chemotherapy-Free Lymphoma Treatment Meets Primary Endpoint in Phase 3 Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2647453719","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647453719?lang=en_us&edition=fundamental","pubTime":"2026-06-30 18:40","pubTimestamp":1782816030,"startTime":"0","endTime":"0","summary":"BeOne Medicines'  Brukinsa met its primary endpoint of progression-free survival in a phase 3 study evaluating the drug as a potential treatment in combination with rituximab for mantle cell lymphoma, the company said Tuesday.The chemotherapy-free drug combination showed \"a highly statistically significant and clinically meaningful improvement\" versus standard of care, the company said.The safety profile was consistent with that of both medicines, the company said.Mantle cell lymphoma is a rare and typically aggressive type of B-cell non-Hodgkin lymphoma, mostly affecting older adults, the company said.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ONC","BK4526","MDCO","BK4585","BK4139","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647327725","title":"Chinese Biopharma Stocks Rally as Investors Favor Healthcare over AI","url":"https://stock-news.laohu8.com/highlight/detail?id=2647327725","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647327725?lang=en_us&edition=fundamental","pubTime":"2026-06-29 17:33","pubTimestamp":1782725580,"startTime":"0","endTime":"0","summary":"Chinese biopharma stocks rallied on Monday, as investors moved away from artificial-intelligence stocks amid concerns over overstretched valuations.Shares of BeOne Medicines led gains among biopharma ","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BPRC5H50.USD","BK1161","LU1808992512.USD","LU0315179316.USD","BK0216","BK4585","HCSG","CHAT","LU1303224171.USD","AGIX","01093","01801","LU1993786604.SGD","LU2039709279.SGD","00241","LU0140636845.USD","02315","IE00BZ08YS42.EUR","600276","LABU","LU1807302812.USD","LU1255011170.USD","BK1583","LU0456827905.SGD","86618","ONC","BK0196","ARTY","BK1502","06618","09637","XBI","AIPO","BK1191","LU1008478684.HKD","BK0028","01877","BK4137","603259","BK0239","BK0012","LU2328871848.SGD","BK1571","ISBC","LU1226287529.USD","688180","BK1189","LU0405327494.USD","XLV","LU1251922891.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1125815089","title":"BEIGENE Subsidiary to Pay Approximately 446 Million Yuan in Back Taxes, No Penalty Involved","url":"https://stock-news.laohu8.com/highlight/detail?id=1125815089","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1125815089?lang=en_us&edition=fundamental","pubTime":"2026-06-26 18:08","pubTimestamp":1782468514,"startTime":"0","endTime":"0","summary":"BEIGENE (ASX: 06160) has announced that a wholly-owned subsidiary in China has received and agreed to a notice from local tax authorities regarding adjustments to previously filed tax returns.The...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","BK4139","BK1583","ONC","688235","BK1588","LU1303224171.USD","LU0588546209.SGD","06160","LU0307460666.USD","LU2328871848.SGD","LU1969619763.USD","LU1770034418.SGD","BK4585","LU1719994722.HKD","BK4588","BK4526","LU1251922891.USD","BK1161","BK1500"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646802037","title":"BeOne Medicines’ Real‑World Lung Cancer Study Puts Tislelizumab Under the Market Microscope","url":"https://stock-news.laohu8.com/highlight/detail?id=2646802037","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646802037?lang=en_us&edition=fundamental","pubTime":"2026-06-26 00:31","pubTimestamp":1782405082,"startTime":"0","endTime":"0","summary":"BeOne Medicines ($ONC) announced an update on their ongoing clinical study. BeOne Medicines (ONC) is running an observational study called “A Real-...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/beone-medicines-realworld-lung-cancer-study-puts-tislelizumab-under-the-market-microscope?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/beone-medicines-realworld-lung-cancer-study-puts-tislelizumab-under-the-market-microscope?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ONC","MDCO","BK4585","BK4526","BK4139","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644808016","title":"BeOne Medicines (ONC) Investors Track New Data from BeiGene’s Chronic Urticaria Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2644808016","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644808016?lang=en_us&edition=fundamental","pubTime":"2026-06-19 00:32","pubTimestamp":1781800347,"startTime":"0","endTime":"0","summary":"BeOne Medicines ($ONC) announced an update on their ongoing clinical study. BeOne Medicines (ONC) investors are watching a new update on a BeiGene ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/beone-medicines-onc-investors-track-new-data-from-beigenes-chronic-urticaria-trial?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/beone-medicines-onc-investors-track-new-data-from-beigenes-chronic-urticaria-trial?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4526","BK4211","BK4588","ISBC","MDCO","ONC","BK4139","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644809090","title":"BeOne Medicines’ BGB-45035 Trial Completion: What Early Skin Data Could Mean for ONC Investors","url":"https://stock-news.laohu8.com/highlight/detail?id=2644809090","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644809090?lang=en_us&edition=fundamental","pubTime":"2026-06-19 00:32","pubTimestamp":1781800331,"startTime":"0","endTime":"0","summary":"BeOne Medicines ($ONC) announced an update on their ongoing clinical study. The Phase 1a/1b study, officially titled “Phase 1a/1b Randomized Study ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/beone-medicines-bgb-45035-trial-completion-what-early-skin-data-could-mean-for-onc-investors?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/beone-medicines-bgb-45035-trial-completion-what-early-skin-data-could-mean-for-onc-investors?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","ISBC","BK4139","BK4526","BGB","BK4211","MDCO","ONC","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162658338","title":"BEIGENE Announces Grant of Share Options, Restricted Share Units, and Performance Share Units","url":"https://stock-news.laohu8.com/highlight/detail?id=1162658338","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1162658338?lang=en_us&edition=fundamental","pubTime":"2026-06-18 21:21","pubTimestamp":1781788869,"startTime":"0","endTime":"0","summary":"The pharmaceutical company BEIGENE (06160) has disclosed the granting of share-based awards to certain recipients.On June 11, 2026, the board of directors, the compensation committee, and/or the...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1500","BK1161","BK4139","LU0588546209.SGD","LU1303224171.USD","BK0239","LU1770034418.SGD","LU0307460666.USD","BK4588","06160","LU1719994722.HKD","LU1969619763.USD","688235","BK4526","BK1583","LU2328871848.SGD","BK1588","ONC","BK4585","LU1251922891.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644370681","title":"BeOne Revenue Expected to Grow on Strong Brukinsa Sales -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2644370681","media":"Dow Jones","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644370681?lang=en_us&edition=fundamental","pubTime":"2026-06-18 16:39","pubTimestamp":1781771940,"startTime":"0","endTime":"0","summary":"0839 GMT - BeOne Medicine's revenue is forecast to reach $6.5 billion in 2026, driven by flagship cancer drug Brukinsa, which helped turn its operating margins positive last year, Morningstar analyst Kai Wang says. He sees the stock as undervalued, citing potential sales growth of its chronic lymphocytic leukemia treatment Brukinsa and its other core product Beqalzi, which is projected to generate $1 billion in sales by 2035. Wang estimates margin expansion of 400 basis points over the long term, as Brukinsa continues to scale out and capture more market share. Beyond 2026, Morningstar forecasts Brukinsa revenue growth in the high teens annually before slowing to 6% by 2032, when its patent expires. It initiates coverage of BeOne's H-shares with a fair value estimate of HK$214. The stock closed at HK$163.70. ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4526","ONC","BK4585","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644728385","title":"BeOne Medicines Advances BGB-58067 With Key Drug-Interaction Study in Healthy Volunteers","url":"https://stock-news.laohu8.com/highlight/detail?id=2644728385","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644728385?lang=en_us&edition=fundamental","pubTime":"2026-06-18 00:32","pubTimestamp":1781713967,"startTime":"0","endTime":"0","summary":"BeOne Medicines ($ONC) announced an update on their ongoing clinical study. BeOne Medicines (ONC) is running a Phase 1 study called “An Open-Label,...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/beone-medicines-advances-bgb-58067-with-key-drug-interaction-study-in-healthy-volunteers?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/beone-medicines-advances-bgb-58067-with-key-drug-interaction-study-in-healthy-volunteers?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4526","MDCO","BGB","ONC","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643276720","title":"BeOne Medicines (ONC) Gets a Buy from Barclays","url":"https://stock-news.laohu8.com/highlight/detail?id=2643276720","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643276720?lang=en_us&edition=fundamental","pubTime":"2026-06-15 16:37","pubTimestamp":1781512665,"startTime":"0","endTime":"0","summary":"In a report released today, Etzer Darout from Barclays maintained a Buy rating on BeOne Medicines, with a price target of $409.00. According to Tip...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/beone-medicines-onc-gets-a-buy-from-barclays-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/beone-medicines-onc-gets-a-buy-from-barclays-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","BK4585","MDCO","BK4139","ONC","BK4526"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642267757","title":"BeOne Says Updated Results for Cancer Drug Tacabrutideg Show 'Durable' Responses","url":"https://stock-news.laohu8.com/highlight/detail?id=2642267757","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642267757?lang=en_us&edition=fundamental","pubTime":"2026-06-12 19:21","pubTimestamp":1781263301,"startTime":"0","endTime":"0","summary":"BeOne Medicines  said Friday that new data for tacabrutideg, a Bruton's tyrosine kinase degrader, showed \"durable responses\" in pretreated relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma patients and promising activity in BTK inhibitor-naive patients.Data from 67 patients with relapsed or refractory CLL/SLL treated with tacabrutideg across multiple dose levels showed an overall response rate of 85.1% and a 24-month progression-free survival rate of 53.8%. BeOne said tacabrutideg was generally well tolerated and no new toxicities were identified.In patients with relapsed or refractory Waldenstrom macroglobulinemia, tacabrutideg achieved a major response rate of 76.3%, a very good partial response rate of 30.2% and a 15-month progression-free survival rate of 70.4%.The data were announced at the European Hematology Association Congress in Stockholm.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4585","BK4139","ONC","BK4588","BK4526"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":7,"pageCount":4,"totalSize":140,"code":"91000000","status":"200"}]}}